Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090960 | 0.82 | OPRD1 (0.45) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL5096902 | 0.81 | OPRD1 (0.48) | OPRD1KCNH2CYP2D6HPGDOPRM1 | |
| SCHEMBL490144 | 0.80 | OPRD1 (0.52) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL490192 | 0.78 | OPRD1 (0.46) | OPRD1KCNH2CYP2D6HPGDMRGPRX2 | |
| SCHEMBL5091002 | 0.76 | OPRD1 (0.40) | OPRD1KCNH2CYP2D6OPRK1 | |
| SCHEMBL5090846 | 0.76 | OPRD1 (0.43) | OPRD1KCNH2CYP2D6LMNAHPGD | |
| SCHEMBL5197746 | 0.75 | CHRM1 (0.36) | OPRD1KCNH2LMNA | |
| SCHEMBL5094869 | 0.75 | PARP14 (0.37) | — | |
| SCHEMBL3384454 | 0.72 | SETD7 (0.44) | OPRD1KCNH2LMNA | |
| SCHEMBL490547 | 0.71 | OPRD1 (0.49) | OPRD1KCNH2CYP2D6HPGDOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885KCNH2 618/4885CYP2D6 359/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885KCNH2 618/4885CYP2D6 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.